February 11, 2020 / 1:43 PM / 11 days ago

BRIEF-Sellas Enrolls First Patient In Early-Stage Trial Of Galinpepimut-S In Combination With Opdivo

Feb 11 (Reuters) - Sellas Life Sciences Group Inc:

* SELLAS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 1 TRIAL OF GALINPEPIMUT-S (GPS) IN COMBINATION WITH NIVOLUMAB (OPDIVO®) IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below